Home / Pharmaceuticals / Kaposi Sarcoma Market By Treatment (Chemotherapy, Immunotherapy, Highly Active Antiretroviral Therapy (HAART), Radiation Therapy, Surgical Procedures) - Growth, Future Prospects, And Competitive Analysis, 2017 -2025

Kaposi Sarcoma Market By Treatment (Chemotherapy, Immunotherapy, Highly Active Antiretroviral Therapy (HAART), Radiation Therapy, Surgical Procedures) - Growth, Future Prospects, And Competitive Analysis, 2017 -2025

Published: Sep 2017 | Report Code: 58687-09-17

Kaposi sarcoma is caused due to the infection of a virus called as Kaposi sarcoma associated herpes virus (KSHV). The disease prevalence is varied around the globe; there are four types of Kaposi sarcoma such as AIDS-KS, immunocompromised, classic or sporadic and endemic. Technological advancement in the drug delivery such as targeted immunotherapy and nanomedicines are utilized to facilitate the cytotoxic payload through the blood vessels in the Kaposi sarcoma tumors which usually develops from the cells that line the lymph or blood vessels.

For the purpose of this study, the global Kaposi sarcoma market is studied in terms of treatment types and geography. The drug classes studied in the report includes chemotherapy which is further categorized as (alkaloids and liposomal anthracyclines), immunotherapy, HAART, radiation therapy and surgical procedures. Market size estimates and forecast of these segments for the period 2015 to 2025 are provided in terms of US$ Mn along with the respective CAGRs for the period 2017 to 2025, considering 2016 as the base year.

The geographic segmentation of the global Kaposi sarcoma market is performed for the regions North America, Europe, Asia Pacific, Latin America and Middle East and Africa. The regions are also further sub-segmented on the basis of major countries:

  • North America
    • U.S.
    • Canada
  • Europe
    • U.K.
    • Germany
    • France
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • Rest of Asia Pacific
  • Latin America
    • Mexico
    • Brazil
    • Rest of Latin America
  • Middle East and Africa
    • GCC
    • Rest of Middle East and Africa

Market size estimates and forecast for these segments for the period 2015 to 2025 are provided in terms of US$ Mn along with the respective CAGRs for the period 2017 to 2025, considering 2016 as the base year.

This report also includes qualitative assessment factors such as market dynamics (drivers, restraints and opportunities) to have a good understanding of the current and anticipated trends in the global Kaposi sarcoma market. Market attractiveness assessment and competitive landscape analysis by key players are also presented in the study. Furthermore, this report concludes with profiling of key market players currently enjoying prominent position in the global Kaposi sarcoma market. The key players profiled in this report are Aphios Corp, Cytori Therapeutics, Inc., Bristol Myers Squibb Company, CytRx Corporation, Eli Lilly and Co., GlaxoSmithKline plc, F.Hoffman La-Roche, Inc., Johnson and Johnson, Merck & Co., Inc., Pfizer, Inc.

Kaposi Sarcoma Market

Chapter 1. Preface
1.1. Report Scope and Description
1.2. Research Methodology
1.2.1. Phase I-Secondary Research
1.2.2. Phase II-Primary Research
1.2.3. Phase III-Expert Panel Review
1.2.4. Assumptions
1.2.5. Approach Adopted

Chapter 2. Executive Summary
2.1. Global Kaposi Sarcoma Market Portraiture
2.1.1. Global Kaposi Sarcoma Market, by Treatment Type, 2016
2.1.2. Global Kaposi Sarcoma Market, by Geography, 2016

Chapter 3. Kaposi Sarcoma: Market Dynamics and Future Outlook
3.1. Market Overview
3.2. Drivers
3.3. Challenges
3.4. Opportunities
3.5. Attractive Investment Proposition, by Geography
3.6. Competitive Landscape
3.6.1. Competitive Landscape, by Key Players, 2016

Chapter 4. Global Kaposi Sarcoma Market, by Treatment Type, 2015 – 2025 (US$ Mn)
4.1. Overview
4.2. Attractive Investment Proposition: Global Kaposi Sarcoma Market, by Treatment Type
4.3. Chemotherapy
4.3.1. Alkaloids
4.3.2. Liposomal Anthracyclines
4.4. Immunotherapy
4.5. Highly Active Antiretroviral Therapy (HAART)
4.6. Radiation Therapy
4.7. Surgical Procedures

Chapter 5. Global Kaposi Sarcoma Market, by Geography, 2015 – 2025 (US$ Mn)
5.1. Overview
5.2. North America Kaposi Sarcoma Market Analysis, 2015 – 2025
5.2.1. North America Kaposi Sarcoma Market, by Treatment Type, 2015 – 2025 (US$ Mn)
5.2.2. North America Kaposi Sarcoma Market, by Country, 2015 – 2025 (US$ Mn)
5.2.2.1. U.S.
5.2.2.2. Canada
5.3. Europe Kaposi Sarcoma Market Analysis, 2015 – 2025
5.3.1. Europe Kaposi Sarcoma Market, by Treatment Type, 2015 – 2025 (US$ Mn)
5.3.2. Europe Kaposi Sarcoma Market, by Country, 2015 – 2025 (US$ Mn)
5.3.2.1. U.K.
5.3.2.2. Germany
5.3.2.3. France
5.3.2.4. Rest of Europe
5.4. Asia Pacific Kaposi Sarcoma Market Analysis, 2015 – 2025
5.4.1. Asia Pacific Kaposi Sarcoma Market, by Treatment Type, 2015 – 2025 (US$ Mn)
5.4.2. Asia Pacific Kaposi Sarcoma Market, by Country, 2015 – 2025 (US$ Mn)
5.4.2.1. Japan
5.4.2.2. China
5.4.2.3. India
5.4.2.4. Rest of APAC
5.5. Latin America Kaposi Sarcoma Market Analysis, 2015 – 2025
5.5.1. Latin America Kaposi Sarcoma Market, by Treatment Type, 2015 – 2025 (US$ Mn)
5.5.2. Latin America Kaposi Sarcoma Market, by Country, 2015 – 2025 (US$ Mn)
5.5.2.1. Brazil
5.5.2.2. Mexico
5.5.2.3. Rest of Latin America
5.6. Middle East & Africa (MEA) Kaposi Sarcoma Market Analysis, 2015 – 2025
5.6.1. MEA Kaposi Sarcoma Market, by Treatment Type, 2015 – 2025 (US$ Mn)
5.6.2. MEA Kaposi Sarcoma Market, by Region, 2015 – 2025 (US$ Mn)
5.6.2.1. GCC
5.6.2.2. Rest of MEA

Chapter 6. Company Profiles
6.1. Aphios Corp.
6.1.1. Business Description
6.1.2. Financial Information (Subject to data availability)
6.1.3. Product Portfolio
6.1.4. Key Developments
6.2. Bristol Myers Squibb Company
6.3. Cytori Therapeutics, Inc.
6.4. CytRx Corporation
6.5. Eli Lilly and Co.
6.6. GlaxoSmithKline plc.
6.7. F.Hoffman La-Roche, Inc.
6.8. Johnson and Johnson
6.9. Merck & Co., Inc.
6.10. Pfizer, Inc.
6.11. Other Notable Players

List of Tables :

TABLE 1 Global Kaposi Sarcoma Market, by Treatment Type, 2015 – 2025 (US$ Mn)
TABLE 2 Global Kaposi Sarcoma Market, by Geography, 2015 – 2025 (US$ Mn)
TABLE 3 North America Kaposi Sarcoma Market, by Treatment Type, 2015 – 2025 (US$ Mn)
TABLE 4 North America Kaposi Sarcoma Market, by Country, 2015 – 2025 (US$ Mn)
TABLE 5 Europe Kaposi Sarcoma Market, by Treatment Type, 2015 – 2025 (US$ Mn)
TABLE 6 Mn)
TABLE 7 Europe Kaposi Sarcoma Market, by Country, 2015 – 2025 (US$ Mn)
TABLE 8 Asia Pacific Kaposi Sarcoma Market, by Treatment Type, 2015 – 2025 (US$ Mn)
TABLE 9 Asia Pacific Kaposi Sarcoma Market, by Country, 2015 – 2025 (US$ Mn)
TABLE 10 Latin America Kaposi Sarcoma Market, by Treatment Type, 2015 – 2025 (US$ Mn)
TABLE 11 Latin America Kaposi Sarcoma Market, by Country, 2015 – 2025 (US$ Mn)
TABLE 12 Middle East and Africa Kaposi Sarcoma Market, by Treatment Type, 2015 – 2025 (US$ Mn)
TABLE 13 Middle East and Africa Kaposi Sarcoma Market, by Region, 2015 – 2025 (US$ Mn)
TABLE 14 Aphios Corp.: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 15 Bristol Myers Squibb Company: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 16 Cytori Therapeutics, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 17 CytRx Corporation: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 18 Eli Lilly and Co.: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 19 GlaxoSmithKline plc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 20 F.Hoffman La-Roche, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 21 Johnson and Johnson: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 22 Merck & Co., Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 23 Pfizer, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)

List of Figures :

FIG. 1 Kaposi Sarcoma: Market Segmentation
FIG. 2 Global Kaposi Sarcoma Market Share, by Treatment Type, 2016 (Value %)
FIG. 3 Global Kaposi Sarcoma Market Share, by Geography, 2016 (Value %)
FIG. 4 Attractive Investment Proposition, by Geography
FIG. 5 Market Competition Landscape, by Key Players, 2016
FIG. 6 Global Chemotherapy Market, 2015 – 2025 (US$ Mn)
FIG. 7 Global Alkaloids Market, 2015 – 2025 (US$ Mn)
FIG. 8 Global Liposomal Anthracyclines Market, 2015 – 2025 (US$ Mn)
FIG. 9 Global Immunotherapy Market, 2015 – 2025 (US$ Mn)
FIG. 10 Global HAART Market, 2015 – 2025 (US$ Mn)
FIG. 11 Global Radiation Therapy Market, 2015 – 2025 (US$ Mn)
FIG. 12 Global Surgical Procedures Market, 2015 – 2025 (US$ Mn)
FIG. 13 U.S. Kaposi Sarcoma Market, 2015 – 2025 (US$ Mn)
FIG. 14 Canada Kaposi Sarcoma Market, 2015 – 2025 (US$ Mn)
FIG. 15 U.K. Kaposi Sarcoma Market, 2015 – 2025 (US$ Mn)
FIG. 16 Germany Kaposi Sarcoma Market, 2015 – 2025 (US$ Mn)
FIG. 17 France Kaposi Sarcoma Market, 2015-2025 (US$ Mn)
FIG. 18 Rest of Europe Kaposi Sarcoma Market, 2015 – 2025 (US$ Mn)
FIG. 19 Japan Kaposi Sarcoma Market, 2015 – 2025 (US$ Mn)
FIG. 20 China Kaposi Sarcoma Market, 2015 – 2025 (US$ Mn)
FIG. 21 India Kaposi Sarcoma Market, 2015 – 2025 (US$ Mn)
FIG. 22 Rest of Asia Pacific Kaposi Sarcoma Market, 2015 – 2025 (US$ Mn)
FIG. 23 Brazil Kaposi Sarcoma Market, 2015 – 2025 (US$ Mn)
FIG. 24 Mexico Kaposi Sarcoma Market, 2015 – 2025 (US$ Mn)
FIG. 25 Rest of Latin America Kaposi Sarcoma Market, 2015 – 2025 (US$ Mn)
FIG. 26 GCC Kaposi Sarcoma Market, 2015 – 2025 (US$ Mn)
FIG. 27 Rest of Middle East and Africa Kaposi Sarcoma Market, 2015 – 2025 (US$ Mn)

Based on treatment types, the global Kaposi Sarcoma market is categorized into

  • Chemotherapy
    • Alkaloids
    • Liposomal Anthracyclines
  • Immunotherapy
  • Highly Active Antiretroviral Therapy (HAART)
  • Radiation Therapy
  • Surgical Procedures

Kaposi Sarcoma Market

The Kaposi sarcoma market is driven by factors such as rising prevalence of AIDs related Kaposi sarcoma, increasing number of iatrogenically immunocompromised patients and urgent requirement for novel drug discovery in treating subtypes such as classic Kaposi sarcoma found in the Eastern Mediterranean region. In addition, increasing number of diagnostic centers and increasing physician awareness regarding disease etiology will propel the deep market penetration for Kaposi sarcoma. In 2016, highly active antiretroviral therapy (HAART) segment held the largest market share due to factors such as rising prevalence of AIDS, as patients suffering with HIV infection are prone to develop Kaposi sarcoma etiology and the proactive government initiative such as United States Presidents Emergency Plan for AIDS Relief (PEPFAR) to fight AIDS-KS.

Chemotherapy will be the fastest growing segment throughout the forecast period 2017-2025 majorly due to factors such as technological advancement in the drug formulation for e.g. paclitaxel nanosomal formulation utilized as a topical treatment for AIDS-KS surpassing the drug biotransformation which is toxic to liver cells. Promising pipeline with excellent bioequivalence studies such as AT-0918 (Cytori Therapeutics, Inc.). Aldoxorubicin (CytRx Corporation) utilizes acid sensitive linker that selectively binds to albumin to allow the cytotoxic payload to accumulate near the tumor and spare the surrounding healthy tissues. The major players in kaposi sarcoma market are Aphios Corp, Cytori Therapeutics, Inc., Bristol Myers Squibb Company, CytRx Corporation, Eli Lilly and Co., GlaxoSmithKline plc, F.Hoffman La-Roche, Inc., Johnson and Johnson, Merck & Co., Inc., Pfizer, Inc.

For the purpose of this study, the global kaposi sarcoma market is categorized into the following regional and country specific markets:

  • North America
    • U.S.
    • Canada
  • Europe
    • U.K.
    • Germany
    • France
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East and Africa
    • GCC
    • Rest of Middle East and Africa

Kaposi Sarcoma Market

North America was observed to be the largest market for kaposi sarcoma in the base year 2016. According to the American Cancer Society in 2016 the occurrence rate of kaposi sarcoma was 6 cases per million people. More prevalent in the Afro-American men. The dominance of North America is mainly attributed to the presence of key drivers such as rising prevalence of AIDS-KS, affordable reimbursement scenario and developed research and healthcare institutions. The market growth in Europe is mainly attributed to the presence of major pharmaceutical players involved in kaposi sarcoma research and rising public health awareness resulting into early disease diagnosis and treatment. Asia Pacific was observed as the fastest growing regional segment throughout the forecast period 2017-2025. Factors that are anticipated to propel the market growth are increasing number of AIDS patients with kaposi sarcoma complications, increasing disposable incomes and supportive regulatory environment for kaposi sarcoma drug products. Moreover, factors such as developing health infrastructure and proactive government initiatives to fight AIDS-KS in the untapped market of remote areas with unmet medical needs are going to fuel the rapid growth of kaposi sarcoma market in Latin America, and Middle East and Africa in the near future.   

Choose License Type
Connect With Us
+1-800-361-8290
24/7 Research Support

Credence Webinars

Join Credence analysts to explore the latest IT Trends

view upcoming webinars

Our Clients